title: Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era.
abstract: We reviewed consolidation therapy results and analyzed postremission outcomes for 1464 children less than 21 years old at diagnosis in five consecutive Children's Cancer Group acute myeloid leukemia trials between 1979 and 1996. Children in remission were allocated to allogeneic bone marrow transplantation (BMT) (N=373) in first remission, if a matched family donor was available. Remaining children were assigned consolidation chemotherapy (N=688) or autologous purged BMT (N=217), or withdrew from study before assignment, or with unknown data (N=186). Overall and disease-free survival were superior for children assigned allogeneic transplants. High (>50,000/microl) diagnostic white blood cell (WBC) count was prognostic for inferior outcome, but French-American-British (FAB) subtypes were not. Inv(16) is a favorable karyotypic feature for children in first remission and t(8;21) is not. Allogeneic transplantation benefit was evident in most children, including those with high or low diagnostic WBC count, each FAB subtype, and t(8;21), but was not seen in children with inv(16). Therefore, these data suggest reserving matched related donor allogeneic transplantation for children with inv(16) for second remission, but not those with t(8;21).
authors.affiliation: University of Southern California Keck School of Medicine, Los Angeles, CA 91066-0064, USA. talonzo@childrensoncologygroup.org
authors.forename: T A
authors.initials: TA
authors.lastname: Alonzo
authors.forename: R J
authors.initials: RJ
authors.lastname: Wells
authors.forename: W G
authors.initials: WG
authors.lastname: Woods
authors.forename: B
authors.initials: B
authors.lastname: Lange
authors.forename: R B
authors.initials: RB
authors.lastname: Gerbing
authors.forename: A B
authors.initials: AB
authors.lastname: Buxton
authors.forename: S
authors.initials: S
authors.lastname: Neudorf
authors.forename: J
authors.initials: J
authors.lastname: Sanders
authors.forename: F O
authors.initials: FO
authors.lastname: Smith
authors.forename: S A
authors.initials: SA
authors.lastname: Feig
mesh_terms: D000208:Acute Disease; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D003131:Combined Modality Therapy; D006801:Humans; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000235:genetics / Q000401:mortality* / Q000628:therapy*; D017063:Outcome Assessment, Health Care; D011379:Prognosis; D012074:Remission Induction; D016019:Survival Analysis; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents